

🌐 English🌐 Central/Eastern Europe, Middle East & Africa - English



(<https://www.medtronic.com/me-en/index.html>)

Resolute Onyx DES

for coronary artery disease

Resolute Onyx™ is a drug-eluting stent (DES) that's different by design, optimised for complex PCI, and proven safe and effective in real-world, high bleeding risk patients on 1-month dual antiplatelet therapy (DAPT).¹

MENU

Download Brochure(opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/Resolute-Onyx-Product-Brochure.pdf)

Resolute Onyx DES is different by design to address your DES needs and a wide range of patient anatomies. It features:

- Best-in-class deliverability²
- Enhanced visibility with thinner struts²
- Smooth side branch access²
- Fast healing³
- The broadest diameter range

Product Features

Best-in-class deliverability

Single-wire design

Resolute Onyx DES is made from a single wire, which gives it a fluid range of motion and provides the flexibility needed for best-in-class deliverability.²

MENU

Sinusoid-formed wire

Helical wrap

Laser-fused

The Only DES Designed from a Single Wire[‡]

Proven components for optimal healing

Watch a short video to learn more about the BioLinx™ polymer.

- Single-wire design provides a fluid range of motion and the conformability needed for superior strut apposition.²
- BioLinx biocompatible polymer provides superior thromboresistance.⁴
- When combined, fast healing occurs as evidenced by nearly 90% strut coverage at 30 days,³ providing the foundation for the Onyx ONE Global Trial.
- The Onyx ONE Global Trial analysed real-world, high bleeding risk patients on 1-month DAPT treated with a Resolute Onyx DES or a BioFreedom™* DCS.
- Results showed Resolute Onyx DES was safe and effective,¹ providing the option to shorten DAPT in patients who are at high bleeding risk.
- Based on these results, Resolute Onyx DES was the first DES CE-indicated for HBR patients on 1-month DAPT.

See the Onyx ONE Data (<https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html>)

MENU

Enhanced visibility with thinner struts

Platinum-iridium core within Resolute Onyx DES increases visibility for accurate stent placement without compromising strut thickness.²

Resolute Onyx cobalt alloy shell and platinum-iridium core

1. Cobalt alloy shell
2. Platinum iridium core

Smooth side branch access

Resolute Onyx DES has round struts to create a smooth passage when accessing the side branch and lower the propensity to catch during bifurcation procedures.²

Rounded strut cross-section

1. Resolute Onyx DES

MENU

Broadest diameter range

- Complex PCI requires a broad DES size matrix to match a wide range of patient anatomies.
- Resolute Onyx is the only DES with diameters ranging from 2.0 mm to 5.0 mm to treat a broad range of coronary vessel sizes.

Diameter (mm)	Stent Length (mm)									Maximum Expansion Capabilities (MSID [†]) (mm)
	8	12	15	18	22	26	30	—	—	
2.00	8	12	15	18	22	26	30	—	—	3.50 [‡]
2.25	8	12	15	18	22	26	30	34	38	3.50 [‡]
2.50	8	12	15	18	22	26	30	34	38	3.50 [‡]
2.75	8	12	15	18	22	26	30	34	38	4.00 [‡]
3.00	8	12	15	18	22	26	30	34	38	4.00 [‡]

3.50	8	12	15	18	22	26	30	34	38	5.00 [‡]
4.00	8	12	15	18	22	26	30	34	38	5.00 [‡]
4.50	—	12	15	18	22	26	30	—	—	6.00 [‡]
5.00	—	12	15	18	22	26	30	—	—	6.00 [‡]

Product Details

Stent Length (mm)	Stent Length (mm)						
	8	12	15	18	22	26	30
2.00	RONYX20008X	RONYX20012X	RONYX20015X	RONYX20018X	RONYX20022X	RONYX20026X	F
2.25	RONYX22508X	RONYX22512X	RONYX22515X	RONYX22518X	RONYX22522X	RONYX22526X	F
2.50	RONYX25008X	RONYX25012X	RONYX25015X	RONYX25018X	RONYX25022X	RONYX25026X	F
2.75	RONYX27508X	RONYX27512X	RONYX27515X	RONYX27518X	RONYX27522X	RONYX27526X	F
3.00	RONYX30008X	RONYX30012X	RONYX30015X	RONYX30018X	RONYX30022X	RONYX30026X	F
3.50	RONYX35008X	RONYX35012X	RONYX35015X	RONYX35018X	RONYX35022X	RONYX35026X	F
4.00	RONYX40008X	RONYX40012X	RONYX40015X	RONYX40018X	RONYX40022X	RONYX40026X	F

4.50	N/A	RONYX45012X	RONYX45015X	RONYX45018X	RONYX45022X	RONYX45026X	F
5.00	N/A	RONYX50012X	RONYX50015X	RONYX50018X	RONYX50022X	RONYX50026X	F

Maximum expansion capabilities

Reference only in markets where the Resolute Onyx coronary stent and the 0.25 mm expansion have been approved.

Additional Resources

Onyx ONE Global Trial

First randomised, 1-month DAPT trial comparing a DES to a DES in ~2000 high bleeding risk patients on 1-month DAPT.

[Review the Data \(https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html\)](https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html)

Resolute Onyx DES is optimised for complex PCI

Resolute Onyx DES design exclusives make it ideal for complex cases.

[See How](https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/complex-lesions.html) (<https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/complex-lesions.html>)


Bifurcation education

View five techniques that highlight Resolute Onyx DES through endoscopic imaging captured inside an isolated and reanimated beating porcine heart.

[Visit and Bookmark](/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story_html5.html) (opens new window) (/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story_html5.html)

MENU

Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk,⁵ as well as rapid, complete, and functional endothelial healing.^{\$4}

 **Onyx One Results Brochure** (.pdf) (opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf)

This brochure presents clinical evidence about Onyx One.
307KB

(opens new window) (/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf)

Request more information

[Contact us](/me-en/about/contact-us.html?src=cardiovascular.html) (</me-en/about/contact-us.html?src=cardiovascular.html>)

*

As per April 2021.

†

Medtronic and Medtronic logo are trademarks of Medtronic. Third-party trademarks ("™†") belong to their respective owners. All other brands are trademarks of a Medtronic entity.

‡

Including Resolute Integrity™ DES, part of the Medtronic DES portfolio.

§

porcine models.

MENU

References

1

Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. March 26, 2020;382(13):1208-1218.

2

Based on bench test data on file at Medtronic. May not be indicative of clinical performance.

3

Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Adv Interv Cardiol*. 2019;15(2):143-150.

4

Jinnouchi H, Sato Y, Cheng Q, et al. *Int J Cardiol*. March 2021;327:52-57.

[\(mailto:?\)](mailto:?(mailto:?body=https%3A%2F%2Fwww.medtronic.com%2Fme-en%2Fhealthcare-professionals%2Fproducts%2Fcardiovascular%2Fstents%2Fresolute-onyx-des.html))

body=https%3A%2F%2Fwww.medtronic.com%2Fme-en%2Fhealthcare-professionals%2Fproducts%2Fcardiovascular%2Fstents%2Fresolute-onyx-des.html)

MENU



[Patients and Caregivers](#)

[Overview \(https://www.medtronic.com/me-en/your-health.html\)](https://www.medtronic.com/me-en/your-health.html)

[Healthcare Professionals](#)

[Overview \(https://www.medtronic.com/me-en/healthcare-professionals.html\)](https://www.medtronic.com/me-en/healthcare-professionals.html)

[Our company](#)

[Key facts \(https://www.medtronic.com/me-en/our-company/key-facts.html\)](https://www.medtronic.com/me-en/our-company/key-facts.html)

[Leadership \(https://www.medtronic.com/me-en/our-company/leadership.html\)](https://www.medtronic.com/me-en/our-company/leadership.html)

[Mission \(https://www.medtronic.com/me-en/our-company/mission.html\)](https://www.medtronic.com/me-en/our-company/mission.html)

[Career Opportunities \(/me-en/about/careers.html\)](/me-en/about/careers.html)

[Locations \(https://www.medtronic.com/me-en/our-company/locations.html\)](https://www.medtronic.com/me-en/our-company/locations.html)

[Our impact](#)

[Overview \(https://www.medtronic.com/me-en/our-impact.html\)](https://www.medtronic.com/me-en/our-impact.html)

[Privacy Statement \(/me-en/privacy-statement.html\)](/me-en/privacy-statement.html)

[Terms of Use \(/me-en/terms-of-use.html\)](/me-en/terms-of-use.html)

[Contact \(https://www.medtronic.com/me-en/about/contact-us.html\)](https://www.medtronic.com/me-en/about/contact-us.html)

MENU

UC201804678a EE Last Updated February 2023 © 2023 Medtronic